AU2023265968A1 - Compositions and methods for epigenetic regulation of pcsk9 expression - Google Patents
Compositions and methods for epigenetic regulation of pcsk9 expression Download PDFInfo
- Publication number
- AU2023265968A1 AU2023265968A1 AU2023265968A AU2023265968A AU2023265968A1 AU 2023265968 A1 AU2023265968 A1 AU 2023265968A1 AU 2023265968 A AU2023265968 A AU 2023265968A AU 2023265968 A AU2023265968 A AU 2023265968A AU 2023265968 A1 AU2023265968 A1 AU 2023265968A1
- Authority
- AU
- Australia
- Prior art keywords
- domain
- sequence
- human
- seq
- peptide linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
- C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
- C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y201/00—Transferases transferring one-carbon groups (2.1)
- C12Y201/01—Methyltransferases (2.1.1)
- C12Y201/01037—DNA (cytosine-5-)-methyltransferase (2.1.1.37)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263337167P | 2022-05-01 | 2022-05-01 | |
| US202263337164P | 2022-05-01 | 2022-05-01 | |
| US63/337,167 | 2022-05-01 | ||
| US63/337,164 | 2022-05-01 | ||
| US202263355083P | 2022-06-23 | 2022-06-23 | |
| US63/355,083 | 2022-06-23 | ||
| PCT/US2023/066436 WO2023215711A1 (en) | 2022-05-01 | 2023-05-01 | Compositions and methods for epigenetic regulation of pcsk9 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023265968A1 true AU2023265968A1 (en) | 2024-12-19 |
Family
ID=86732155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023265968A Pending AU2023265968A1 (en) | 2022-05-01 | 2023-05-01 | Compositions and methods for epigenetic regulation of pcsk9 expression |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4519293A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516294A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250060954A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119836432A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023265968A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3251776A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL316722A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024013483A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023215711A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311610A (en) | 2021-09-21 | 2024-05-01 | Scribe Therapeutics Inc | Engineered CASX suppressor systems |
| CN119998446A (zh) | 2022-06-07 | 2025-05-13 | 斯克里贝治疗公司 | 用于靶向pcsk9的组合物和方法 |
| CA3260237A1 (en) | 2022-06-24 | 2023-12-28 | Tune Therapeutics, Inc. | Compositions, systems and methods for reducing low-density lipoprotein by targeted gene repression |
| EP4590820A2 (en) * | 2022-09-22 | 2025-07-30 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease |
| JP2026523341A (ja) | 2023-05-15 | 2026-07-14 | エヌクロマ・バイオ,インコーポレーテッド | Hbv遺伝子発現のエピジェネティック調節のための組成物および方法 |
| WO2024238723A1 (en) * | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| EP4735603A2 (en) * | 2023-06-30 | 2026-05-06 | nChroma Bio, Inc. | Guide rna compositions |
| WO2025106739A1 (en) * | 2023-11-14 | 2025-05-22 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of htt expression |
| WO2025137650A2 (en) * | 2023-12-21 | 2025-06-26 | Nchroma Bio, Inc. | Compositions and methods for epigenetic editing |
| WO2025160155A1 (en) * | 2024-01-22 | 2025-07-31 | The Broad Institute, Inc. | Epigenetic targeting of prion diseases |
| WO2025167914A1 (zh) * | 2024-02-07 | 2025-08-14 | 益杰立科新加坡有限公司 | 通过表观编辑多靶点治疗疾病的方法 |
| TW202617754A (zh) * | 2024-06-21 | 2026-05-01 | 大陸商益杰立科(上海)生物科技有限公司 | 靶向b型肝炎病毒基因的工程化基因轉錄阻抑工具及其用途 |
| CN122295445A (zh) * | 2024-06-21 | 2026-06-26 | 益杰立科(上海)生物科技有限公司 | 通过表观编辑靶向调节pcsk9的方法及其用途 |
| TW202617755A (zh) * | 2024-06-21 | 2026-05-01 | 大陸商益杰立科(上海)生物科技有限公司 | 靶向pcsk9的工程化基因轉錄阻抑工具及其用途 |
| WO2025261473A1 (zh) * | 2024-06-21 | 2025-12-26 | 益杰立科(上海)生物科技有限公司 | 工程化基因转录阻抑工具及其用途 |
| WO2026064753A1 (en) | 2024-09-23 | 2026-03-26 | Tune Therapeutics, Inc. | Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing |
| WO2026158158A1 (zh) * | 2025-01-23 | 2026-07-30 | 锐正基因(苏州)有限公司 | 一种向导rna、其组合物及其在编辑pcsk9基因中的应用 |
| WO2026161895A1 (en) | 2025-01-27 | 2026-07-30 | Tune Therapeutics, Inc. | Compositions, systems, and methods for epigenetic regulation of lipoprotein a (lpa) gene expression |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| EP2566972B1 (en) | 2010-05-03 | 2020-01-15 | Sangamo Therapeutics, Inc. | Compositions for linking zinc finger modules |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| EP3443081A4 (en) * | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
| AU2019255789B2 (en) * | 2018-04-19 | 2025-11-20 | The Regents Of The University Of California | Compositions and methods for gene editing |
| AU2019282149B2 (en) | 2018-06-05 | 2025-08-21 | Life Edit Therapeutics, Inc. | RNA-guided nucleases and active fragments and variants thereof and methods of use |
| CN116234902A (zh) | 2020-05-04 | 2023-06-06 | 利兰·斯坦福青年大学托管委员会 | 用于激活和沉默基因表达的效应物结构域的生成、鉴定和表征的组合物、系统和方法 |
| EP4158009A4 (en) * | 2020-06-02 | 2024-10-02 | The Regents of the University of California | Compositions and methods for gene editing |
| AU2021409729A1 (en) * | 2020-12-22 | 2023-07-13 | Nchroma Bio, Inc. | Compositions and methods for epigenetic editing |
| EP4437092A1 (en) * | 2021-11-26 | 2024-10-02 | Epigenic Therapeutics Inc. | Method of modulating pcsk9 and uses thereof |
-
2023
- 2023-05-01 CN CN202380051043.XA patent/CN119836432A/zh active Pending
- 2023-05-01 AU AU2023265968A patent/AU2023265968A1/en active Pending
- 2023-05-01 WO PCT/US2023/066436 patent/WO2023215711A1/en not_active Ceased
- 2023-05-01 CA CA3251776A patent/CA3251776A1/en active Pending
- 2023-05-01 JP JP2024564785A patent/JP2025516294A/ja active Pending
- 2023-05-01 IL IL316722A patent/IL316722A/en unknown
- 2023-05-01 EP EP23729624.9A patent/EP4519293A1/en active Pending
- 2023-05-01 KR KR1020247039938A patent/KR20250060954A/ko active Pending
-
2024
- 2024-10-31 MX MX2024013483A patent/MX2024013483A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024013483A (es) | 2025-04-02 |
| CN119836432A (zh) | 2025-04-15 |
| JP2025516294A (ja) | 2025-05-27 |
| WO2023215711A9 (en) | 2024-01-04 |
| EP4519293A1 (en) | 2025-03-12 |
| KR20250060954A (ko) | 2025-05-07 |
| CA3251776A1 (en) | 2023-11-09 |
| IL316722A (en) | 2024-12-01 |
| WO2023215711A1 (en) | 2023-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4519293A1 (en) | Compositions and methods for epigenetic regulation of pcsk9 expression | |
| AU2023347320A1 (en) | Compositions and methods for epigenetic regulation of hbv gene expression | |
| KR20250044484A (ko) | 표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법 | |
| US20250387518A1 (en) | Compositions and methods for epigenetic regulation of b2m expression | |
| WO2024186896A2 (en) | Compositions and methods for epigenetic regulation of pcsk9 expression | |
| KR20260032655A (ko) | Hbv 유전자 발현의 후성유전학적 조절을 위한 조성물 및 방법 | |
| WO2024229020A2 (en) | Compositions and methods for epigenetic regulation of pcsk9 expression | |
| WO2024145615A2 (en) | Compositions and methods for epigenetic regulation of angptl3 expression | |
| WO2026102011A1 (en) | Compositions and methods for epigenetic regulation of gene expression | |
| WO2025049303A1 (en) | Compositions and methods for epigenetic regulation | |
| WO2025101979A1 (en) | Compositions and methods for epigenetic regulation of genes for treatment of non-alcoholic steatohepatitis or metabolic dysfunction-associated steatohepatitis | |
| EP4544057A1 (en) | Compositions and methods for epigenetic regulation of trac expression | |
| WO2024081879A1 (en) | Compositions and methods for epigenetic regulation of cd247 expression | |
| WO2025049789A1 (en) | Compositions and methods for epigenetic regulation of adora2a expression | |
| EP4544058A1 (en) | Compositions and methods for epigenetic regulation of ciita expression | |
| WO2025019807A2 (en) | Compositions and methods for epigenetic regulation of rfxap expression | |
| WO2025264819A1 (en) | Compositions and methods for epigenetic regulation of znf410 expression | |
| WO2025049792A1 (en) | Compositions and methods for epigenetic regulation of tgfbr2 expression | |
| WO2025038840A1 (en) | Compositions and methods for epigenetic editing | |
| WO2025030130A1 (en) | Methods and compositions comprising dnmt3a-binding antibodies | |
| WO2024178402A2 (en) | Compositions and methods for epigenetic regulation of complement factor expression | |
| WO2024238679A2 (en) | Compositions and methods for epigenetic regulation of cd3gamma, cd3delta, and rfx5 expression | |
| WO2025106739A1 (en) | Compositions and methods for epigenetic regulation of htt expression | |
| WO2025106523A1 (en) | Compositions and methods for epigenetic regulation of f8 expression |